Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Anti-interferon antibodies: a perspective.

R A Figlin¹, L M Itri

¹Department of Medicine, UCLA School of Medicine 90024.

Seminars in Hematology

|July 1, 1988

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.

British journal of cancer·2017

Same author

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

European journal of cancer (Oxford, England : 1990)·2014

Same author

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

British journal of cancer·2014

Same author

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.

British journal of cancer·2012

Patients can develop neutralizing antibodies to interferons, potentially impacting treatment response. Higher doses and longer treatment durations increase antibody formation, necessitating further research into influencing factors.

Area of Science:

Immunology
Pharmacology
Biochemistry

Background:

Clinical trials indicate patients can develop neutralizing antibodies to both natural and recombinant alpha and beta interferons.
Variability in trial design and antibody assay sensitivity complicates the evaluation of factors influencing antibody formation and clinical impact.

Purpose of the Study:

To evaluate factors influencing the development of neutralizing antibodies to interferons.
To assess the clinical significance of these antibodies in patient treatment outcomes.

Main Methods:

Analysis of data from clinical trials involving alpha and beta interferons.
Comparison of antibody formation across different trial designs, protein sources, and administration routes.

Related Experiment Videos

Main Results:

Neutralizing antibodies to recombinant alpha interferons were linked to decreased therapy response in some patients, especially those with B-cell disorders.
Antibody formation is generally associated with longer treatment durations and higher interferon doses, leading to increased cumulative protein exposure.
Factors such as protein source, administration route, and underlying disease may also influence antibody development.

Conclusions:

The development of neutralizing antibodies to interferons is influenced by multiple factors including treatment duration, dosage, protein type, and administration route.
Further research is crucial to identify patients at higher risk for antibody formation and to quantify the clinical effects for improved management strategies.